HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

455.205

+2.9820.66%

Number of Gainers:18

Number of Losers:27

Number of Flat:6

PE:- -

High:456.328

Open:451.993

Low:448.760

Close:452.224

Volume:128.30M

Turnover:3.82B

Market Cap:2.90T

Float Cap:2.00T

Loading ...

Jinxin Fertility Plans Women's Health-Focused Translational Medicine Platform

MT Newswires Live

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

Morgan Stanley Suggests Market Misreads Li Ning's Decline Linked to Haidilao Shareholder Move

Hong Kong Stock Market Highlights: JXR Advances Female Health Translational Medicine Platform

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

AK Medical Sets Dividend Payout Floor at 55% for Fy2026, 60% for Fy2027-28

AK Medical - Announces Fy2027 and Fy2028 Dividend Payout Ratio Increased to not Less than 60%

THOMSON REUTERS

AK Medical - Announces Fy2026 Dividend Payout Ratio Increased to not Less than 55%

THOMSON REUTERS

Haidilao's Corporate Shift to Digitized Management Signals Waning Store-Centric Narrative

Hbm Holdings Says Solstice Oncology Launches Series a Financing Round

Lee's Pharm Secures Exclusive Rights to Develop and Market Novel PARP1 Inhibitor Across Greater China and Southeast Asia

Shandong Boan Biotech Confirms RMB 75 Million Finance Lease Asset Sale Price in Supplemental Pact

Everest Medicines Unit Enters Supply, Distribution Cooperation Contract

MT Newswires Live

SUNAC SERVICES Spends Nearly HK$164,000 to Buy Back 200,000 Shares

Sunac Services Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation

Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion

JXR Allocates HK$2.99 Million to Buy Back 1.35 Million Shares

HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations

HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer

Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BK1583/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":455.20538,"timestamp":1789614691114,"preClose":452.22354,"halted":0,"volume":128296191,"delay":0,"changeRate":0.006594,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.981842,"latestTime":"09-17 11:11:32","open":451.9927,"high":456.3283,"low":448.7602,"amount":3820423322,"amplitude":0.016735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789617600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":2.05901,"peRate":43.493003,"turnoverRate":0.001236,"increases":18,"decrements":27,"flats":4,"marketCap":2901489596464,"floatMarketCap":2003704471248},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":456.3283,"amplitude":0.016735,"preClose":452.22354,"low":448.7602,"pbRate":"2.05901","latestPrice":455.20538,"volume":128296291,"delay":0,"open":451.9927,"prevYearClose":503.90085,"prevWeekClose":450.903,"prevMonthClose":473.951,"prevQuarterClose":402.118,"fiveDayClose":453.486,"twentyDayClose":491.104,"sixtyDayClose":397.417,"secType":"PLATE","market":"HK","turnoverRate":0.001236,"peRate":43.493003,"marketCap":2901489596464,"floatMarketCap":2003704471248,"timestamp":1789614692530,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":18,"down":27,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666557272","title":"Jinxin Fertility Plans Women's Health-Focused Translational Medicine Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2666557272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666557272?lang=en_us&edition=fundamental","pubTime":"2026-09-10 13:57","pubTimestamp":1789019837,"startTime":"0","endTime":"0","summary":"Jinxin Fertility (HKG:1951) plans to develop a translational medicine platform focused mainly on women's health, building on its existing reproductive medicine and research capabilities.The platform w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01951","BK1583","BK1597","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199145560","title":"Tellgen's Subsidiary Device Registration Application Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:54","pubTimestamp":1789012483,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (SZSE: 300642) has announced that its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently had its medical device registration application accepted for review...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300642","BK0042","HART","09996","BK1574","PTH","GDOC","RSPH","LGHT","MEDX","159883","AGNG","MDEV","BK0046","BK0239","BK1583","LNGR","IEIH","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102937814","title":"Morgan Stanley Suggests Market Misreads Li Ning's Decline Linked to Haidilao Shareholder Move","url":"https://stock-news.laohu8.com/highlight/detail?id=1102937814","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102937814?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:20","pubTimestamp":1789006824,"startTime":"0","endTime":"0","summary":"Morgan Stanley has flagged that Li Ning shares took a hit on Wednesday due to negative sentiment tied to the major shareholder sell-down at Haidilao, but the brokerage argues the market may be...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","LU1102505762.USD","LU0106831901.USD","LU1244550577.SGD","IAI","LU0048580855.USD","LU1162221912.USD","LU1548497426.USD","LU0882574139.USD","LU0098860793.USD","LU0234570918.USD","IE00B775SV38.USD","LU1989772923.USD","LU0528227936.USD","LU1102505929.USD","BK1589","BK1604","BK4516","LU2133065610.SGD","LU0106261372.USD","LU1791710582.SGD","LNNGY","BK1512","IE00BKVL7J92.USD","LU0557290698.USD","BK4581","LU2357305700.SGD","LU0314104364.USD","LU1048588211.SGD","82331","LU0912757837.SGD","BK4127","LU0267386448.USD","LU2347655156.SGD","IE00B3S45H60.SGD","LU1244550221.USD","LU0225283273.USD","BK1591","LU1988902786.USD","LU2488822045.USD","LU0541502299.USD","LU2264538146.SGD","LU2125910500.SGD","LU2089283258.USD","LU0795875086.SGD","LU1064131342.USD","LU0593848301.USD","LU0370786039.SGD","LU1244550494.USD","LU1720051108.HKD","LU2487616109.SGD","LU0053666078.USD","LU2045819591.USD","LU1720051017.SGD","LU1880383366.USD","BK1610","LU0823426480.USD","06862","LU1732799900.SGD","BK1583","LU2111349929.HKD","BK4588","LU0327786744.USD","LU0541501648.USD","KBWB","BK1233","LU1363072403.SGD","BK4504","LU2089284900.SGD","LU1791710400.SGD","LU0795875169.SGD","LU0006306889.USD","LU1668664300.SGD","BK1502","LU1732800096.USD","BK4534","LU0320765646.SGD","LU0210528500.USD","LU0390134368.USD","BK4585","LU0158827948.USD","LU2023251221.USD","LU1074936037.SGD","LU2028103732.USD","LU0971096721.USD","BK1227","02331","LU2271345857.HKD","LU0572944931.SGD","LU0072462343.USD","MS","LU0348805143.USD","IE00BZ1G4Q59.USD","LU0823426308.USD","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171834211","title":"Hong Kong Stock Market Highlights: JXR Advances Female Health Translational Medicine Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1171834211","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171834211?lang=en_us&edition=fundamental","pubTime":"2026-09-10 09:04","pubTimestamp":1789002291,"startTime":"0","endTime":"0","summary":"JXR (01951) announced plans to further develop a translational medicine platform primarily focused on female health, marking a strategic move to strengthen its presence in this specialized...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1574","02142","BK4585","FHCO","00950","00580","BK1219","BK1191","BK1161","01951","BK1583","KCAI","BK1189","BK4588","VXUS","BK1116","06681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","01302","BK1583","PTH","09996","HART","RSPH","BK1600","AGNG","GDOC","159883","LGHT","BK1100","MDEV","IEIH","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666472558","title":"AK Medical Sets Dividend Payout Floor at 55% for Fy2026, 60% for Fy2027-28","url":"https://stock-news.laohu8.com/highlight/detail?id=2666472558","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666472558?lang=en_us&edition=fundamental","pubTime":"2026-09-10 06:06","pubTimestamp":1788991597,"startTime":"0","endTime":"0","summary":"AK Medical sets dividend payout floor at 55% for FY2026, 60% for FY2027-28Board adopted a shareholder dividend distribution and return plan covering the three financial years ending Dec. 31, 2028.Divi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL10YD75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1585","BK1617","01789","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584715","title":"AK Medical - Announces Fy2027 and Fy2028 Dividend Payout Ratio Increased to not Less than 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584715?lang=en_us&edition=fundamental","pubTime":"2026-09-10 06:06","pubTimestamp":1788991595,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45116Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","BK1617","BK1583","BK1100","01789"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558479","title":"AK Medical - Announces Fy2026 Dividend Payout Ratio Increased to not Less than 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558479?lang=en_us&edition=fundamental","pubTime":"2026-09-10 06:06","pubTimestamp":1788991595,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45116Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","BK1617","01789","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148899489","title":"Haidilao's Corporate Shift to Digitized Management Signals Waning Store-Centric Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=1148899489","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148899489?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:50","pubTimestamp":1788969027,"startTime":"0","endTime":"0","summary":"China's catering leader Haidilao (06862.HK) experienced a rare high-volume sell-off on September 9, with shares plunging 9.14% and total turnover reaching HK$3.78 billion. The stock's turnover rate...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159792","160636","BK1591","06862","BK1589","BK1583","BK1233","LU2488822045.USD","BK1604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666753136","title":"Hbm Holdings Says Solstice Oncology Launches Series a Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2666753136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666753136?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:20","pubTimestamp":1788967253,"startTime":"0","endTime":"0","summary":"Sept 9 (Reuters) - Hbm Holdings Ltd <2142.HK>::*SOLSTICE ONCOLOGY LAUNCHES $225 MILLION SERIES A FINANCING ROUND*Further company coverage: 2142.HK* ((Reuters.Briefs@thomsonreuters.com;))((Reuters Inve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nRSD12sC1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183555429","title":"Lee's Pharm Secures Exclusive Rights to Develop and Market Novel PARP1 Inhibitor Across Greater China and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=1183555429","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183555429?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:40","pubTimestamp":1788964828,"startTime":"0","endTime":"0","summary":"Lee's Pharm (00950) has announced that its wholly-owned subsidiary, Lee's Pharm (Hong Kong) Limited, has entered into an exclusive licensing agreement with US-based biotechnology firm 1cBio, Inc. to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1191","BK1587","00950","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535062","title":"Shandong Boan Biotech Confirms RMB 75 Million Finance Lease Asset Sale Price in Supplemental Pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535062","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535062?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:31","pubTimestamp":1788960667,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotech confirms RMB 75 million finance lease asset sale price in supplemental pactShandong Boan Biotechnology signed a supplemental agreement on Sep. 9, 2026 for its finance lease with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLsF4wJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0028","BK1161","BK0183","02186","06955","BK1606","LU1781817850.SGD","BK0015","LU1048596156.SGD","BK0278","LU1580142542.USD","BK0188","LU0572939691.SGD","LU0572940350.SGD","HK0000181112.HKD","BK0187","601166","BK1583","HK0000181138.USD","BK0012","LU0264606111.USD","LU1328615791.USD","LU0821914370.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535781","title":"Everest Medicines Unit Enters Supply, Distribution Cooperation Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535781","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535781?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:26","pubTimestamp":1788960412,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) unit Everest Medicines (China) entered into a strategic cooperation framework agreement with Hasten Biopharmaceutical.The contract is for the supply, distribution, and rel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","01952","MDCO","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181637025","title":"SUNAC SERVICES Spends Nearly HK$164,000 to Buy Back 200,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1181637025","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181637025?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:41","pubTimestamp":1788957664,"startTime":"0","endTime":"0","summary":"SUNAC SERVICES (01516) has announced that on September 9, 2026, it utilised approximately HK$163,900 to repurchase 200,000 of its own shares.The buyback reflects the company's ongoing capital management strategy in the current market environment.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1229","BK1542","01516","BK1583","BK1258"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533521","title":"Sunac Services Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533521","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533521?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:36","pubTimestamp":1788957409,"startTime":"0","endTime":"0","summary":"Sunac Services files HKEX next-day return disclosing share buyback for cancellationSunac Services filed a next-day disclosure return reporting an on-market repurchase of 200,000 shares on Sept. 9.Repu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLLwsnr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1258","BK1229","01516","01918","BK1585","BK1240","BK1555","BK1521","BK1583","BK1542"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113083232","title":"Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1113083232","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113083232?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956296,"startTime":"0","endTime":"0","summary":"Everest Medicines (01952) has announced the signing of a strategic cooperation framework agreement with Hissen on September 9, 2026, under which both parties have agreed to establish a framework for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152232199","title":"JXR Allocates HK$2.99 Million to Buy Back 1.35 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1152232199","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152232199?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:50","pubTimestamp":1788954639,"startTime":"0","endTime":"0","summary":"On September 9, 2026, JXR (01951.HK) executed a share repurchase, investing HK$2.9931 million to acquire 1.3515 million of its own shares.The buyback was conducted at a price range of HK$2.2 to HK$2.25 per share, as disclosed in the company's official announcement.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","BK1583","BK1597","01951"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173908290","title":"HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1173908290","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173908290?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:18","pubTimestamp":1788952700,"startTime":"0","endTime":"0","summary":"HBM Holdings (02142) has announced that its partner company Solstice Oncology (Solstice) has successfully completed a $225 million Series A funding round and officially commenced operations. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587460","title":"HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587460","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587460?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952514,"startTime":"0","endTime":"0","summary":"HBM partner Solstice Oncology launches Phase 2 trial of porustobart in neoadjuvant MSS stage II-III colon cancerHBM Holdings’ partner Solstice Oncology launched with a USD 225 million Series A to adva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL71K3Mm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666163587","title":"Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666163587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666163587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:12","pubTimestamp":1788952368,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUAC6DRXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":9,"totalSize":327,"code":"91000000","status":"200"}]}}